D. Boral Capital reaffirmed their buy rating on shares of Carisma Therapeutics (NASDAQ:CARM – Free Report) in a research note released on Monday,Benzinga reports. D. Boral Capital currently has a $12.00 price target on the stock.
A number of other equities research analysts have also issued reports on the company. Robert W. Baird lowered Carisma Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $10.00 to $1.00 in a research report on Thursday, December 12th. Baird R W lowered Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. BTIG Research lowered Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. Evercore ISI reissued an “in-line” rating and issued a $0.70 target price (down previously from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th. Finally, EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Carisma Therapeutics has an average rating of “Hold” and a consensus price target of $4.94.
Get Our Latest Stock Report on CARM
Carisma Therapeutics Trading Down 7.0 %
Carisma Therapeutics (NASDAQ:CARM – Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting analysts’ consensus estimates of ($0.31). Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. The company had revenue of $3.39 million for the quarter. Sell-side analysts anticipate that Carisma Therapeutics will post -1.32 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in CARM. Wexford Capital LP boosted its stake in shares of Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Carisma Therapeutics during the 2nd quarter worth approximately $40,000. Finally, Barclays PLC boosted its stake in shares of Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after acquiring an additional 549,290 shares during the period. Institutional investors and hedge funds own 44.27% of the company’s stock.
Carisma Therapeutics Company Profile
Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.
Further Reading
- Five stocks we like better than Carisma Therapeutics
- Dividend Capture Strategy: What You Need to Know
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- How to Calculate Inflation Rate
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.